Back to Search Start Over

Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP).

Authors :
Nielsen M
Franken PF
Reinards TH
Weiss MM
Wagner A
van der Klift H
Kloosterman S
Houwing-Duistermaat JJ
Aalfs CM
Ausems MG
Bröcker-Vriends AH
Gomez Garcia EB
Hoogerbrugge N
Menko FH
Sijmons RH
Verhoef S
Kuipers EJ
Morreau H
Breuning MH
Tops CM
Wijnen JT
Vasen HF
Fodde R
Hes FJ
Source :
Journal of medical genetics [J Med Genet] 2005 Sep; Vol. 42 (9), pp. e54.
Publication Year :
2005

Abstract

Objective: To investigate the contribution of MYH associated polyposis coli (MAP) among polyposis families in the Netherlands, and the prevalence of colonic and extracolonic manifestations in MAP patients.<br />Methods: 170 patients with polyposis coli, who previously tested negative for APC mutations, were screened by denaturing gradient gel electrophoresis and direct sequencing to identify MYH germline mutations.<br />Results: Homozygous and compound heterozygous MYH mutations were identified in 40 patients (24%). No difference was found in the percentage of biallelic mutation carriers between patients with 10-99 polyps or 100-1000 polyps (29% in both groups). Colorectal cancer was found in 26 of the 40 patients with MAP (65%) within the age range 21 to 67 years (median 45). Complete endoscopic reports were available for 16 MAP patients and revealed five cases with gastro-duodenal polyps (31%), one of whom also presented with a duodenal carcinoma. Breast cancer occurred in 18% of female MAP patients, significantly more than expected from national statistics (standardised morbidity ratio = 3.75).<br />Conclusions: Polyp numbers in MAP patients were equally associated with the attenuated and classical polyposis coli phenotypes. Two thirds of the MAP patients had colorectal cancer, 95% of whom were older than 35 years, and one third of a subset of patients had upper gastrointestinal lesions. Endoscopic screening of the whole intestine should be carried out every two years for all MAP patients, starting from age 25-30 years. The frequent occurrence of additional extraintestinal manifestations, such as breast cancer among female MAP patients, should be thoroughly investigated.

Details

Language :
English
ISSN :
1468-6244
Volume :
42
Issue :
9
Database :
MEDLINE
Journal :
Journal of medical genetics
Publication Type :
Editorial & Opinion
Accession number :
16140997
Full Text :
https://doi.org/10.1136/jmg.2005.033217